Relmada Therapeutics (RLMD) Prices Upsized 8.82M Share Offering at $17/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall St set to open higher as tech rebounds, Micron earnings eyed
- Brent hits lowest since before start of Iran war on expectations of smoother oil flows via Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- JPMorgan raises S&P 500 target to 7,800, says earnings revision ’unprecedented’
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
After-Hours Stock Movers 12/08: (RH) (STRM) (APTX) Higher; (RLMD) (GME) (LCID) Lower (more...)
December 8, 2021 5:10 PM ESTAfter-Hours Movers:
RH (NYSE: RH) 10.8% HIGHER; reported Q3 EPS of $7.03, $0.39 better than the analyst estimate of $6.64. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $985.18 million. Now expect fiscal 2021 revenue growth of 32% to 33% versus our prior outlook of 31% to 33%, and adjusted operating margin in the range of 25.3% to 25.5% versus our prior outlook of 24.9% to 25.5%.
Relmada Therapeutics, Inc. (Nasdaq: RLMD) 10.4% LOWER; announced its intention to offer and sell $100 million of shares of its common stock... More
Relmada Therapeutics (RLMD) Announces $100M Proposed Public Offering of Common Stock
December 8, 2021 4:19 PM ESTRelmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced its intention to offer and sell $100 million of shares of its common stock in an underwritten public offering pursuant to its existing shelf registration... More
